FY2024 Earnings Estimate for Moderna Issued By William Blair

Moderna, Inc. (NASDAQ:MRNA - Free Report) - William Blair upped their FY2024 earnings per share (EPS) estimates for Moderna in a research report issued on Tuesday, January 14th. William Blair analyst M. Minter now expects that the company will earn ($8.77) per share for the year, up from their previous forecast of ($9.04). The consensus estimate for Moderna's current full-year earnings is ($9.30) per share. William Blair also issued estimates for Moderna's Q4 2024 earnings at ($2.33) EPS, Q1 2025 earnings at ($2.86) EPS, Q2 2025 earnings at ($2.59) EPS, Q3 2025 earnings at ($0.83) EPS, Q4 2025 earnings at ($0.49) EPS and FY2025 earnings at ($6.76) EPS.

Moderna (NASDAQ:MRNA - Get Free Report) last released its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The business had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.25 billion. During the same period last year, the firm posted ($1.39) earnings per share. The firm's quarterly revenue was up 3.8% compared to the same quarter last year.

Other analysts have also recently issued research reports about the company. JPMorgan Chase & Co. decreased their target price on Moderna from $59.00 to $45.00 and set an "underweight" rating for the company in a research report on Tuesday, November 26th. Royal Bank of Canada restated a "sector perform" rating and set a $75.00 price objective on shares of Moderna in a research report on Thursday, September 19th. Piper Sandler reiterated an "overweight" rating and issued a $69.00 target price (down previously from $115.00) on shares of Moderna in a report on Monday, November 18th. Argus downgraded shares of Moderna from a "buy" rating to a "hold" rating in a research report on Wednesday, December 18th. Finally, Berenberg Bank lifted their target price on shares of Moderna from $33.00 to $42.00 and gave the company a "hold" rating in a research note on Thursday. Four investment analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $75.58.

Moderna Trading Up 0.9 %

Moderna stock traded up $0.30 during midday trading on Friday, reaching $34.06. The stock had a trading volume of 7,919,673 shares, compared to its average volume of 12,035,175. Moderna has a twelve month low of $31.94 and a twelve month high of $170.47. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. The firm has a market cap of $13.11 billion, a price-to-earnings ratio of -5.85 and a beta of 1.60. The firm's fifty day simple moving average is $40.85 and its two-hundred day simple moving average is $66.75.

Insider Buying and Selling

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of the firm's stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the sale, the insider now owns 19,717 shares of the company's stock, valued at $843,690.43. This trade represents a 6.71 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders have sold 2,664 shares of company stock worth $115,210 in the last quarter. 15.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Moderna

Several hedge funds have recently modified their holdings of MRNA. Envestnet Asset Management Inc. boosted its holdings in Moderna by 78.7% in the 2nd quarter. Envestnet Asset Management Inc. now owns 109,733 shares of the company's stock valued at $13,031,000 after purchasing an additional 48,316 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Moderna by 2.1% during the second quarter. Dimensional Fund Advisors LP now owns 1,427,300 shares of the company's stock valued at $169,542,000 after buying an additional 29,566 shares during the last quarter. Edgestream Partners L.P. bought a new stake in shares of Moderna in the second quarter valued at about $1,672,000. Meiji Yasuda Asset Management Co Ltd. grew its position in Moderna by 6.2% during the second quarter. Meiji Yasuda Asset Management Co Ltd. now owns 4,887 shares of the company's stock worth $580,000 after buying an additional 287 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC increased its stake in Moderna by 26.2% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 30,504 shares of the company's stock valued at $3,622,000 after acquiring an additional 6,339 shares during the period. 75.33% of the stock is owned by institutional investors.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.